These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 9002759

  • 1. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 2. 111In-octreotide scintigraphy in pituitary adenomas.
    Tofani A, Cucchi R, Pompili A, Carapella C, Crecco M, Mottolese M, Maini CL.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
    Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M.
    Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
    [Abstract] [Full Text] [Related]

  • 9. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N, Furno A, Sforza A, Chiarini V, Graziano E, Zampa G, Turba E.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
    Tumiati MN, Facchi E, Gatti C, Bossi A, Longari V.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
    [Abstract] [Full Text] [Related]

  • 12. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ.
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA.
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
    Podoba J, Hnilica P, Makaiová I, Kovácová S, Rybár M, Gecík K, Belan V, Steno J.
    Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.